Quantitative contrast-enhanced endoscopic ultrasound in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumors: can we predict survival using perfusion parameters? A pilot study
| العنوان: | Quantitative contrast-enhanced endoscopic ultrasound in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumors: can we predict survival using perfusion parameters? A pilot study |
|---|---|
| المؤلفون: | Alina Liliana, Constantin, Irina, Cazacu, Daniela Elena, Burtea, Irina, Cherciu Harbiyeli, Nona, Bejinariu, Carmen, Popescu, Mircea, Serbanescu, Daniela, Tabacelia, Catalin, Copaescu, Manoop, Bhutani, Cezar, Stroescu, Adrian, Saftoiu |
| المصدر: | Medical Ultrasonography. 24:393 |
| بيانات النشر: | SRUMB - Romanian Society for Ultrasonography in Medicine and Biology, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Acoustics and Ultrasonics, Radiological and Ultrasound Technology, Radiology, Nuclear Medicine and imaging |
| الوصف: | Aim: Contrast-enhanced harmonic endoscopic ultrasound (CEH-EUS) parameters may be used to predict prognosis of pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumors (pNET). The aim of this study was to investigate the association between several perfusion parameters on CEH-EUS performed before treatment and survival outcome in patients with PDAC or pNET.Material and methods: Thirty patients with PDAC or pNET who underwent CEH-EUS and EUS-guided fine needle aspiration (EUS-FNA) were included. Quantitative analysis of tumor vascularity was performed using time-intensity curve (TIC) analysis-derived parameters, obtained from processing CEH-EUS recordings with a commercially available software (VueBox). Cox proportional hazards models were used to determine associations with survival outcome.Results: Median overall survival (OS) for PDAC patients was 9.61 months (95% CI: 0.1-38.7) while the median OS for pNET patients was 15.81 months (95% CI: 5.8-24.75. In a multivariate model for OS, a lower peak enhancement (HR=1.76, p=0.02) and a lower wash-in area under the curve (HR=1.06, p=0.001) were associated with worse survival outcome for patients with PDAC.Conclusions: CEH-EUS parameters may be used as a surrogate to predict PDAC aggressiveness and survival before treatment. After validation by large-scale studies, CEH-EUS perfusion parameters have the potential to be used in pretreatment risk stratification of patients with PDAC and in evidence-based clinical decision support. |
| تدمد: | 2066-8643 1844-4172 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcf7c892e819d6ba63c3d2d43a2aa9abTest https://doi.org/10.11152/mu-3503Test |
| رقم الانضمام: | edsair.doi.dedup.....fcf7c892e819d6ba63c3d2d43a2aa9ab |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20668643 18444172 |
|---|